Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6435197

CC(C)C[C@H](NC(=O)c1ccc2c(Cl)cnc(NC(=N)N)c2c1)C(=O)O.O=C(O)C(F)(F)F

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRN P28799 4/20 0.51
SORT1 Q99523 4/20 0.51
CA2 P00918 3/20 0.48
CA1 P00915 2/20 0.48
DGAT1 O75907 1/20 0.41
F3 P13726 2/20 0.39
CNR2 P34972 1/20 0.38
TP53 P04637 1/20 0.38
MAPK1 P28482 1/20 0.38
PDK1 Q15118 1/20 0.38
PDK2 Q15119 1/20 0.38
PDK3 Q15120 1/20 0.38
PDK4 Q16654 1/20 0.38
MAPK11 Q15759 1/20 0.37
MAPK14 Q16539 1/20 0.37
NTSR1 P30989 1/20 0.36
ITGB3 P05106 1/20 0.36
ITGA2B P08514 1/20 0.36
TMPRSS15 P98073 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL6435207 1.00 GRN (0.51) GRNSORT1CA2CA1DGAT1
Trifluoroacetic Acid SCHEMBL6434379 0.90 CA2 (0.46) GRNSORT1CA2CA1DGAT1
Trifluoroacetic Acid SCHEMBL6434979 0.89 CA2 (0.46) CA2CA1PDK1PDK2PDK3
Trifluoroacetic Acid SCHEMBL6434983 0.89 CA2 (0.46) CA2CA1PDK1PDK2PDK3
Trifluoroacetic Acid SCHEMBL6432685 0.88 CA2 (0.49) CA2CA1PDK1PDK2PDK3
Trifluoroacetic Acid SCHEMBL6432682 0.88 CA2 (0.49) CA2CA1PDK1PDK2PDK3
Trifluoroacetic Acid SCHEMBL6437718 0.86 CA2 (0.45) CA2CA1DGAT1
Trifluoroacetic Acid SCHEMBL6437715 0.86 CA2 (0.45) CA2CA1DGAT1
SCHEMBL6434410 0.84 MAPT (0.45) GRNSORT1CA2CA1MAPK1
SCHEMBL6434387 0.84 MRGPRX4 (0.37) GRNSORT1CA2CA1PDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1077945-B1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER (US) 2003-01-08 EP disclosed
US-6093731-A Isoquinolines PFIZER INC. 2000-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 GRN 87/4885SORT1 692/4885CA2 3285/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 GRN 87/4885SORT1 692/4885CA2 3285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.